Oncology 12 Questions with David Long David Long leads the Oncology Business Unit at MSD in the UK and brings a wealth of experience from his 20 years within the organisation, having held a variety of local, regional and global
Oncology The gut microbiome: the next breakthrough in cancer? Ben Hargreaves discovers how research has emerged outlining how the gut microbiome plays a crucial role in patients’ response to cancer treatments.
R&D Allogeneic therapies: The future of cancer treatment? Allogeneic therapies could provide an answer to some of the drawbacks of autologous therapies.
Oncology World Thrombosis Day at 10, talking blood clots and cancer A new 'Move Against Thrombosis' campaign and discussion of cancer-related blood clotting.
Oncology Better balance of cancer treatment efficacy and toxicity The FDA Oncology Center of Excellence announced its Project Optimus draft guidance in January.
Oncology Pfizer’s bispecific elranatamab and future oncological care Pfizer announced that the FDA granted Priority Review for its BLA for bispecific elranatamab.
News Heart drug developer Kardigan files IPO The steady stream of biotech IPOs on the Nasdaq this year has continued, with Kardigan the latest to make its intention to list known.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.